Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer

We review the clinical trials and observational studies literature regarding the clinical and economic burden of bone metastasis and skeletal-related events (SREs) in prostate cancer, and discuss current gaps in understanding the impact of bone metastasis in this disease. Trial data indicate that SR...

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in oncology Vol. 26; no. 3; p. 274
Main Authors: Yong, Candice, Onukwugha, Eberechukwu, Mullins, C Daniel
Format: Journal Article
Language:English
Published: United States 01.05.2014
Subjects:
Bone Neoplasms - economics
Bone Neoplasms - secondary
Clinical Trials as Topic
Cost of Illness
Fractures, Bone - economics
Fractures, Bone - etiology
Health Care Costs
Humans
Male
Prostatic Neoplasms - economics
Prostatic Neoplasms - pathology
Spinal Cord Compression - economics
Spinal Cord Compression - etiology
ISSN:1531-703X, 1531-703X
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We review the clinical trials and observational studies literature regarding the clinical and economic burden of bone metastasis and skeletal-related events (SREs) in prostate cancer, and discuss current gaps in understanding the impact of bone metastasis in this disease. Trial data indicate that SREs occur in half of prostate cancer patients with bone metastasis in the absence of treatment, and 30-45% among those who receive bone-modifying agents. In the United States, the cost of SRE ranged from $7553 per radiation episode to $88 838 per bone surgery episode. Prevalence of SRE, time to SRE occurrence, and cost of SRE varied across studies because of differences in study populations, follow-up period, and the algorithm used to measure SRE. There is limited evidence on the clinical and economic impact by SRE subtype. Information regarding patient-reported outcomes and costs from the patient's perspective is lacking. Bone metastasis and SREs in prostate cancer patients are associated with considerable morbidity, reduced survival, and substantial economic burden. Consistent study methodology, particularly the measurement of SREs, is necessary to allow comparison of estimates across studies. The inclusion of patient-centered clinical and economic outcomes in future research will provide pertinent information regarding the burden of bone metastasis and SREs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1531-703X
1531-703X
DOI:10.1097/CCO.0000000000000071